Bryan F. Cox

TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.

TL;DR: The present data indicate that a potent and selective antagonist of P 2X3 and P2X2/3 receptors effectively reduces both nerve injury and chronic inflammatory nociception, but P2x3 andP2X 2/3 receptor activation may not be a major mediator of acute, acute inflammatory, or visceral pain.

TL;DR: This Purkinje fiber model detects six of seven drugs linked clinically to acquired long QT syndrome and torsade de pointes, and clears each of five drugs not associated with repolarization abnormalities (overall 92% accuracy), validating the utility of this Purkinjen fiber model in the preclinical evaluation of QT prolongation and proarrhythmic risk by noncardiac drugs.

TL;DR: Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clinical trial in patients administered the antihypertensive, omapatrilat, but the relative contribution of specific BMEs to this effect is unclear and confounded by the lack of a predictive pre‐clinical model of angioEDema.

TL;DR: The vasodilator activity of adenosine has been associated with selective stimulation of A2 receptors and no elevation in cyclic GMP levels could be observed in tissues stimulated with CPA or DPMA, indicating the A1-selective nature of this agonist.